Alexander I. Spira

28.3k citations

506 papers · 9.9k indexed · 8 hit papers · h-index 46

Oncology top 0.2%
Pulmonary and Respiratory Medicine top 0.2%
Molecular Biology top 2%
Cancer Research top 1%
Immunology top 2%

Co-authors: Preston A. Marx D D Ho Steven M. Wolinsky J. Matthew Mahoney Bruce K. Patterson Richard A. Koup Pasi A. Jänne Sai‐Hong Ignatius Ou
Topics: Lung Cancer Treatments and Mutations (198 papers)Colorectal Cancer Treatments and Studies (96 papers)Lung Cancer Research Studies (86 papers)
Cited by: Oncology Virology Pulmonary and Respiratory Medicine
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Nature Medicine
Partner nations: United States Spain United Kingdom

In The Last Decade

Alexander I. Spira

469 papers receiving 9.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

2008 661 citations Alexander I. Spira, Tracey L. Evans et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

2015 576 citations George D. Demetri, Margaret von Mehren et al. Journal of Clinical Oncology profile →
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.

1996 556 citations Alexander I. Spira et al. profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Ramaswamy Govindan, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2022 269 citations Alexander I. Spira, James G. Christensen et al. profile →
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Alexander I. Spira, Jared Weiss et al. profile →
Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation

2023 139 citations Alexander I. Spira, Navid Hafez et al. Journal of Clinical Oncology profile →
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

2024 68 citations Anthony W. Tolcher, Alexander I. Spira et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Alexander I. Spira

Since Specialization

Citations

This map shows the geographic impact of Alexander I. Spira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander I. Spira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander I. Spira more than expected).

Fields of papers citing papers by Alexander I. Spira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander I. Spira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander I. Spira. The network helps show where Alexander I. Spira may publish in the future.

Co-authorship network of co-authors of Alexander I. Spira

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander I. Spira. A scholar is included among the top collaborators of Alexander I. Spira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander I. Spira. Alexander I. Spira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC 2025 ·Clinical Lung Cancer ·Alexander I. Spira,David Berz,Robert M. Jotte,(unknown),Mark S. Berger	0
2	691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation 2024 ·Annals of Oncology ·Alison M. Schram,Gilberto Lopes,(unknown),Elisa Fontana,Thomas B. Karasic,(unknown),Patricia LoRusso,Vanesa Gregorc,(unknown),(unknown),Dominic Richardson,(unknown),Alexander I. Spira,Daniel Shao-Weng Tan,John A. Thompson,Dipesh Uprety,Marc Fellous,Yanguo Qin,Ecaterina E. Dumbrava	2
3	Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer 2024 ·Investigational New Drugs ·Shubham Pant,Byoung Chul Cho,Christos E. Kyriakopoulos,Alexander I. Spira,Nizar M. Tannir,Theresa L. Werner,Xiaohong Yan,Saskia Neuteboom,Richard C. Chao,Sanjay Goel	1
4	1000MO A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors 2024 ·Annals of Oncology ·(unknown),(unknown),(unknown),Patricia LoRusso,Janice M. Mehnert,Alexander I. Spira,(unknown),Omid Hamid,(unknown),Karim A. Benhadji,Leila Alland,Xi Hu,Hong‐Ping Xiao,Xun Bao,(unknown),Yubao Gong,Xuesheng Liu	2
5	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·M. De Miguel,(unknown),Víctor Moreno,(unknown),Jessica Menis,Giuseppe Daniele,Anthony B. El-Khoueiry,Alexander I. Spira,Alessia Gravina,Anthony J. Olszanski,(unknown),(unknown),(unknown),(unknown),(unknown),William D. Hedrich,(unknown),Jinping Gan,Xiaorong Shi,Robert H.I. Andtbacka	0
6	625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications 2024 ·Annals of Oncology ·Marwan Fakih,Davendra Sohal,Justin Call,Susanna V. Ulahannan,(unknown),(unknown),Thomas B. Karasic,Alexander I. Spira,Min Zhong,(unknown),Kishore Hari,Ovidiu C. Trifan,(unknown)	2
7	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira,Byoung Chul Cho,Enriqueta Felip,Edward B. Garon,Kōichi Goto,Melissa Johnson,Natasha B. Leighl,Antonio Passaro,David Planchard,Sanjay Popat,James Chih‐Hsin Yang,Xiaoqian Lu,Yong Jiang,(unknown),(unknown),Marcin Kowanetz,Shirley Wang,John T. Le,Jerry Y. Hsu,Caicun Zhou	0
8	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors 2023 ·SHILAP Revista de lepidopterología ·Jong Chul Park,David Berz,Manish Sharma,Erminia Massarelli,Ralph J. Hauke,Frank Tsai,David S. Hong,(unknown),Justin Call,Jennifer W. Carlisle,Rachel E. Sanborn,Naomi B. Haas,John Hamm,D. Ross Camidge,Alexander I. Spira,(unknown),(unknown),(unknown),Anthony W. Tolcher	2
9	756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors 2023 ·SHILAP Revista de lepidopterología ·Alexander I. Spira,Michael S. Gordon,Jason T. Henry,Sandip Pravin Patel,Kartik Sehgal,Shiraj Sen,Randy F. Sweis,Marsha Crochiere,Shui He,(unknown),(unknown),Bin Zhang,Anthony W. Tolcher	1
10	1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors 2023 ·Annals of Oncology ·Sunil Babu,Shunsuke Kondo,(unknown),Alexander I. Spira,Ruth Perets,Toshihiko Doi,Jair Bar,Andrae Vandross,David Sommerhalder,(unknown),Catherine Tribouley,(unknown),Jung Yong Hong,(unknown),Rachel S. Leibman,John D. Powderly	2
11	1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Julia Rotow,Saiama N. Waqar,K. Papadopoulos,J-Y. Hung,Alexander I. Spira,Hui Gan,Tatsuya Yoshida,(unknown),(unknown),Enriqueta Felip,Kiyotaka Yoh,(unknown),Randy Robinson,Nandini Rudra-Ganguly,(unknown),Byoung Chul Cho	4
12	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) 2023 ·Gynecologic Oncology ·Elizabeth Lee,Jordi Rodón,Michael J. Demeure,Dustin A. Deming,Noah Federman,Meredith McKean,Alexander I. Spira,David J. Kwiatkowski,Maen Hussein,Erlinda M. Gordon,David K. Crockett,Kristen N. Ganjoo,(unknown),Lee D. Cranmer,Anita Schmid,Willis H. Navarro,Loretta M. Itri,Gopa Iyer	1
13	Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies 2021 ·Clinical Cancer Research ·Melissa L. Johnson,Anthony B. El-Khoueiry,Navid Hafez,Nehal J. Lakhani,Hirva Mamdani,Jordi Rodón,Rachel E. Sanborn,(unknown),Valentina Boni,Mark Stroh,Alison L. Hannah,Song Wang,Henry Castro,Alexander I. Spira	45
14	620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion 2021 ·Annals of Oncology ·Eugene Shenderov,(unknown),Piotr J. Wysocki,Wen Xu,Rodryg Ramlau,Andrew Weickhardt,Jakub Żołnierek,Alexander I. Spira,Anthony M. Joshua,John D. Powderly,Emmanuel S. Antonarakis,(unknown),Jeanny B. Aragon‐Ching,Jiayu Shen,Channing J. Paller,Nicholas J. Vogelzang,Kirsten Leu,Javier Cortés,Chet Bohac,Iwona Ługowska	21
15	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia 2020 ·Clinical Cancer Research ·Amer M. Zeidan,Maya Ridinger,Tara L. Lin,Pamela S. Becker,Gary J. Schiller,Prapti A. Patel,Alexander I. Spira,Michaela L. Tsai,Errin Samuëlsz,Sandra Silberman,Mark G. Erlander,Eunice S. Wang	57
16	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors 2019 ·Clinical Cancer Research ·Rastislav Bahleda,Antoîne Italiano,Cinta Hierro,Alain C. Mita,Andrés Cervantes,Nancy Chan,Mark M. Awad,Emiliano Calvo,Víctor Moreno,Ramaswamy Govindan,Alexander I. Spira,(unknown),Bob Zhong,(unknown),Italo Poggesi,Trilok Parekh,Hong Xie,Jeffrey R. Infante,Josep Tabernero	187
17	Detection of NRG1 Gene Fusions in Solid Tumors 2019 ·Clinical Cancer Research ·Sushma Jonna,Rebecca Feldman,Jeffrey Swensen,Zoran Gatalica,W. Michael Korn,Hossein Borghaei,C. Patrick,Jorge J. Nieva,Alexander I. Spira,Ari M. Vanderwalde,Antoinette J. Wozniak,Edward S. Kim,Stephen V. Liu	155
18	Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy 2018 ·Annals of Oncology ·(unknown),Alexander I. Spira,Collin M. Blakely,Kai He,David Berz,Donald Richards,(unknown),Abigail L. Savage,(unknown),Erminia Massarelli,Robert M. Jotte,(unknown),James G. Christensen,Peter Olson,Vanessa Tassell,Leora Horn	9
19	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations 2017 ·Clinical Cancer Research ·Helena A. Yu,Alexander I. Spira,Leora Horn,Jared Weiss,Howard West,Giuseppe Giaccone,Tracey L. Evans,Ronan J. Kelly,(unknown),Andrew Krivoshik,Diarmuid Moran,Srinivasu Poondru,Fei Jie,(unknown),Anne Keating,Geoffrey R. Oxnard	23
20	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trialbreakdown → 2015 ·Journal of Clinical Oncology ·George D. Demetri,Margaret von Mehren,Robin L. Jones,Martee L. Hensley,Scott M. Schuetze,Arthur P. Staddon,Mohammed Milhem,A. Elias,Kristen N. Ganjoo,Hussein A. Tawbi,Brian Andrew Van Tine,Alexander I. Spira,Andrew Dean,Nushmia Z. Khokhar,Youn Choi Park,Roland E. Knoblauch,Trilok Parekh,Robert G. Maki,Shreyaskumar Patel	576

About Alexander I. Spira

Alexander I. Spira is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 506 papers that have together received 9.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (198 papers), Colorectal Cancer Treatments and Studies (96 papers) and Lung Cancer Research Studies (86 papers). The work is most often cited by research in Oncology (5.9k citations), Virology (718 citations) and Pulmonary and Respiratory Medicine (4.6k citations). Alexander I. Spira has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Preston A. Marx, D D Ho, Steven M. Wolinsky, J. Matthew Mahoney, Bruce K. Patterson, Richard A. Koup, Pasi A. Jänne, Sai‐Hong Ignatius Ou, Karen Velastegui and David R. Spigel. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact